---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-032462"
form_type: "8-K"
ticker: null
cik: "0001113148"
company_name: "INFINITY PHARMACEUTICALS, INC."
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T13:41:56.261210+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Infinity Pharma receives Nasdaq delisting notice for bid price noncompliance; plans appeal

## Summary
- Nasdaq Staff determined to delist INFI for failure to regain compliance with minimum $1.00 bid price within 180-day period that began Dec 28, 2022.
- Delisting scheduled for July 7, 2023 unless Company requests hearing by July 5, 2023; Company intends to request hearing.
- Company also remains out of compliance with Nasdaq's market value of listed securities rule (minimum $50M) with grace period expiring October 2, 2023.
- Hearing Panel can grant extension through December 26, 2023; no guarantee of regaining compliance.

## SEC filing metadata
- accession: 0001140361-23-032462
- form_type: 8-K
- cik: 0001113148
- company_name: INFINITY PHARMACEUTICALS, INC.
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1113148/000114036123032462/0001140361-23-032462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1113148/000114036123032462/brhc20055271_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-032462
- JSON: https://secwatch.observer/filing/0001140361-23-032462.json
- Plain text: https://secwatch.observer/filing/0001140361-23-032462.txt

## Key facts
- Listing & Compliance Notices
  INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: April 4, 2023, the Company also received a deficiency letter from the Staff of Nasdaq notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) for continued listing on The Nasdaq Global Select Market, as the market value of the Company’s listed securities was less than $50,000,000 for the previous 30 consecutive business days and the Company does not meet any of the alternative listing requirements. The Company was granted a 180-day grace period to regain compliance with this requirement, which expires on October 2, 2023. As o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123032462/0001140361-23-032462-index.htm
- Listing & Compliance Notices
  INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: rom the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined to delist the Company’s common stock from The Nasdaq Global Select Market due to the Company not having regained compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”) during the 180-calendar-day period (the “Compliance Period”) following the deficiency letter the Company received from the Staff on December 28, 2022, regarding the Company’s noncompliance with the Minimum Bid Requirement, the receipt of which the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123032462/0001140361-23-032462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.